Weight regain data worry investors mulling Zepbound potential

With all eyes on the growing market for obesity therapies, recent results from a trial of Eli Lilly’s (NYSE: LLY) newly-approved weight loss drug Zepbound (tirzepatide) may be cause for concern.

Full results from the SURMOUNT-4 study, published in The Journal of the American Medical Association, show that the trial met the primary endpoint of mean percent change in body weight, and all key secondary endpoints, compared to placebo.

However, people taking Zepbound regained a significant amount of weight after stopping treatment for a year.